Recursion Pharmaceuticals, Inc. (RXRX) Earnings History
Net Loss7 years of earnings data (2019–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Recursion Pharmaceuticals, Inc. (RXRX) Earnings Overview
As of November 8, 2026, Recursion Pharmaceuticals, Inc. (RXRX) reported trailing twelve-month net income of -$476M, reflecting +14.8% year-over-year growth. The company earned $-0.88 per diluted share over the past four quarters, with a net profit margin of -863.4%.
Looking at the long-term picture, RXRX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$63M in fiscal 2019.
Recursion Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including SDGR (-$59M net income, -40.4% margin), ABCL (-$165M net income, -194.9% margin), RLAY (-$294M net income, -1800.6% margin), RXRX has room to improve margins relative to the peer group. Compare RXRX vs SDGR →
RXRX Earnings vs Peers
Earnings metrics vs comparable public companies
RXRX Historical Earnings Data (2019–2025)
7 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$645M | -39.1% | -$648M | $-1.44 | -863.4% | -867.9% |
| 2024 | -$464M | -41.3% | -$479M | $-1.69 | -788.0% | -814.1% |
| 2023 | -$328M | -37.0% | -$350M | $-1.58 | -747.7% | -797.8% |
| 2022 | -$239M | -28.4% | -$246M | $-1.36 | -603.5% | -619.3% |
| 2021 | -$186M | -114.3% | -$183M | $-1.05 | -1864.8% | -1827.8% |
| 2020 | -$87M | -39.2% | -$85M | $-0.52 | -2549.3% | -2479.2% |
| 2019 | -$63M | - | -$62M | $-0.37 | -3654.3% | -3649.4% |
Download Data
Export RXRX earnings history in CSV or JSON format
Free sign-in required to download data
RXRX Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
7+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
RXRX — Frequently Asked Questions
Quick answers to the most common questions about buying RXRX stock.
What is RXRX earnings per share (EPS)?
RXRX trailing twelve-month (TTM) diluted EPS is $-0.88, reflecting +14.8% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2019 to 2025 is available in the table on this page.
What is Recursion Pharmaceuticals, Inc.'s net income?
Recursion Pharmaceuticals, Inc. (RXRX) trailing twelve-month net income is $-476M as of 2025. Earnings grew +14.8% year-over-year.
Is RXRX profitable?
RXRX is not currently profitable on a TTM basis, reporting a net loss of $-476M. Net margin is -863.4%. Investors should monitor for a return to profitability.
What is RXRX's earnings growth rate?
RXRX compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2019 to 2025.
What are RXRX's profit margins?
Recursion Pharmaceuticals, Inc. net profit margin is -863.4%, operating margin is -867.9%, and gross margin is -62.0%. Below-average margins reflect competitive or cost pressures. Return on Equity is -59.5%.
Is RXRX growing earnings?
RXRX is growing earnings steadily. YoY EPS growth of +14.8% is consistent with the 5-year CAGR of N/A. TTM net income is $-476M.
What was RXRX's best earnings year?
Recursion Pharmaceuticals, Inc.'s highest annual net income on record is $-63M, achieved in fiscal year 2019. Earnings history on this page spans 2019 to 2025 and includes all annual and quarterly figures.
What were RXRX's earnings last quarter?
RXRX's most recent reported quarter was Q3 2026. Net income was $-119M with diluted EPS of $-0.22. For a full breakdown of all quarters, see the quarterly earnings table on this page.